Novo Nordisk rebrands to 'Novo,' unveils corporate changes as it fights for obesity market share
Why now
Thesis: Novo rebrand amid obesity competition, no fundamental change
Catalyst to watch: Obesity market share data vs Lilly
Main risk: Lilly remains share-gain threat
Why it matters
Novo rebranding is a marketing/identity move amid obesity-drug competition; it does not change fundamentals, and Lilly remains the share-gain threat.
Details
The Danish drugmaker called the changes the beginning of a new chapter for the company, which faces stiff competition from Eli Lilly.
Sources
- cnbc · 2026-09-14 07:00 UTC